EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Sunday, June 23rd 2019 at 7:22pm UTC Parexel FSP provides biopharmaceutical customers the full spectrum of outsourcing solutions from full service to functional to a hybrid approach across a range of specialized disciplines including Clinical, Data Management, Safety, Regulatory and Medical Affairs BOSTON & DURHAM, N.C.–(BUSINESS WIRE)– Parexel, a leading …
Plus »SCIEX Announces Co-Marketing Agreement with EluciData to Break Down Barriers Faced by Metabolomics Researchers
Friday, June 21st 2019 at 4:41pm UTC SCIEX and EluciData to Offer an End-to-End Data Processing Pipeline for all Metabolomics Workflows in a Single Cloud-based Environment FRAMINGHAM, Mass.–(BUSINESS WIRE)– SCIEX, a global leader in life science analytical technologies, announces a co-marketing agreement with EluciData, a disruptive integrated Omics platform company …
Plus »Novanta to Present at the CJS Securities 19th Annual “New Ideas” Summer Conference on Tuesday, July 9, 2019
Thursday, June 20th 2019 at 8:10pm UTC BEDFORD, Mass.–(BUSINESS WIRE)– Novanta Inc. (Nasdaq: NOVT) (the « Company »), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the CJS Securities 19th Annual “New Ideas” Summer Conference on …
Plus »FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene
Friday, June 21st 2019 at 6:30pm UTC -SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation- -Vertex’s third medicine approved to treat the underlying cause of CF in eligible patients in this age …
Plus »Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
Friday, June 21st 2019 at 11:00am UTC ?Preclinical Proof of Concept for Oral Delivery Achieved, Demonstrating Robust, Dose-Dependent Silencing of Liver-Expressed Target in Rodents, with Durability Profile Similar to Subcutaneous Administration – ? Company Also Reports on New Advances in CNS and Ocular Delivery, Demonstrating Durable and Efficacious Target Silencing …
Plus »Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Friday, June 21st 2019 at 8:01pm UTC BEDFORD, Mass.–(BUSINESS WIRE)– Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company that is pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its initial public offering of 9,074,776 shares of …
Plus »Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy
Friday, June 21st 2019 at 1:45pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy (DMD). Edasalonexent is a …
Plus »Dicerna™ Presents Additional Data from PHYOX™1 Study of DCR-PHXC in Patients with Primary Hyperoxaluria Type 1 (PH1) and Type 2 (PH2)
Friday, June 21st 2019 at 11:30am UTC —Researchers Report Substantial Oxalate Reduction Following Single-Dose Administration of DCR-PHXC in Additional Patients with PH2— —Enrollment Underway in Pivotal PHYOX2 Trial of DCR-PHXC— CAMBRIDGE, Mass.–(BUSINESS WIRE)– DicernaTM Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of ribonucleic acid interference (RNAi) …
Plus »Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
Friday, June 21st 2019 at 12:00pm UTC DEXTENZA® Now Approved for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery BEDFORD, Mass.–(BUSINESS WIRE)– class= »bwalignl »> Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, …
Plus »The 12th Annual BioPharm America™ Offers Top Quality Networking With Global Life Science Leaders in September
Friday, June 21st 2019 at 12:00pm UTC CARLSBAD, Calif.–(BUSINESS WIRE)– The twelfth annual international partnering conference, BioPharm America™, will take place at the Boston Convention & Exhibition Center, September 11–12. During two impactful days, the event will deliver unequaled value and unparalleled access to global decision makers and innovative biotech …
Plus »
